VivaDiag SARS-CoV-2 Ag Fast Check tugineb immuunanalüüsi oskusteabele SARS-CoV-2 nukleokapsiidi valgu antigeeni kiireks ja kvalitatiivseks tuvastamiseks inimese orofarünksi või ninaneelu tampooniproovides. Kontroll annab lõpptulemuse 15 minuti jooksul, selgitades välja COVID-19-ga saastunud isikud, kes aitavad kiiresti kaasa viiruse levikule.
Pakett sisaldab kõiki vajalikke vidinaid koos tampooni, väljatõmbetoru, ekstraheerimise eraldusvõime ja külgmise ringluse kontrollsüsteemiga. Selle kontrolli kasutamiseks ei ole vaja spetsiaalset varustust ega personali. Hinnanguid võivad läbi viia haritud töötajad igal ajal ja igal ajal, st ainult kvalifitseeritud kasutamiseks
See külgvereringe Covid-19 kiire antigeeni kontrollimise seade on haritud personalil hõlpsasti õigete tulemuste saavutamiseks, kasutades kiiresti neelu- või ninaneelu tampooniproovi.
Kui proov on kogutud, sisestage tampoon ekstraheerimise eraldusvõimega täidetud ekstraheerimistorusse. Pärast suletud pakendist testimissüsteemi eemaldamist lisage kolm tilka vastust ja oodake 15 minutit varem kui tšeki uurimine, mis näitab selgelt optimistlikku või kahjulikku tulemust.
Selle Covid-19 kiire antigeenikontrolli seadme üldine täpsus on 98,79%, spetsiifilisus 99,12% ja tundlikkus 90,90%, mis tagab täieliku kindluse kiirete, õigete ja usaldusväärsete tulemuste kohta.
Neid hinnanguid tuleb kasutada osana täielikult sisseehitatud COVID-19 tehnikast, mille abil määratakse need saastunud, et vähendada viiruse levikut. VivaDiag ™ SARS-CoV-2 Ag Fast Check on loodud AINULT täiendava kontrollina, kui kahtlustatakse koronaviiruse kahjuliku nukleiinhappe avastamist, või koos nukleiinhappe tuvastamisega kahtlustatavate juhtumite analüüsimisel. Nukleokapsiidi valgu antigeeni testimise tulemusi ei tohiks kasutada ainsa tõelise alusena SARS-CoV-2 (COVID-19) nakkuse diagnoosimiseks või välistamiseks või nakkuse seismiseks.
Ettekirjutus ja mõeldud kasutamine
Immupass VivaDiag SARS-CoV-2 Ag Fast Check on mõeldud meditsiinilaboritele ja kvalifitseeritud tervishoiutöötajatele ainult hoolduspunktide testimiseks. Mitte koduseks testimiseks.
Immupass VivaDiag ™ SARS-CoV-2 Ag Fast Check tugineb immuunanalüüsi oskusteabele. Igas kontrollisüsteemis on tuvastusliinil (T-joon) üks rida SARS-vastaseid koronaviiruse monoklonaalseid antikehi ja üks rida hiirevastaseid IgG-polüklonaalseid antikehi standardsel juhtimisliinil (C-joon).
Kui ekstraheeritud proov on proovile korralikult lisatud, peaks see reageerima märgistatud antikehaga, et sisestada peen, kombinatsioon migreerub seejärel membraani kaudu kapillaarliigutusega ja interakteerub kaetud SARS-vastase koronaviiruse monoklonaalse antikehaga. Kui proov sisaldab SARS-CoV-2 antigeeni, tundub tuvastusjoon lillakaspunane, mis näitab, et SARS-CoV-2 antigeen on optimistlik . Igal muul juhul on kontrolli lõpptulemus kahjulik . Kontrollisüsteem sisaldab lisaks tippkvaliteediga juhtimisliini C, mis peaks kõigi õigustatud hinnangute puhul tunduma lillakaspunane. Kui tavaline haldusliin C ei tundu, on kontrolli lõpptulemus kehtetu isegi siis, kui tuvastusjoon tundub.
Koostis
Iga tšekipakett sisaldab: 25 tšekividinat, 25 väljatõmbetoru (eeltäidetud ekstraheerimise eraldusvõimega 300 μL / tuub), filtreeritud düüse, 1 tuubialust, 25 steriilset tampooni ja 1 kimp.
Vajalikke tarvikuid ei saanud siiski tarnida: taimer.
SARS-CoV-2 Rapid Antigen Test Nasal |
|||
| 9901-NCOV-03G | Roche Diagnostics | 25 Tests/Kit | EUR 94 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
|||
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) |
|||
| IOV87952 | INVBIO | 20T/kit | EUR 39 |
|
Description: Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronvirus antigen. It will provide information for clinical doctors to prescribe correct medications. |
|||
Ag rapid CDV Ag Test Kit |
|||
| RG11-03 | Bionote | 1 box | EUR 138.2 |
|
Description: Please check the datasheet of Ag rapid CDV Ag Test Kit before using the test. |
|||
Ag Rapid AIV Ag Test Kit |
|||
| RG15-01 | Bionote | 1 box/30 tests | EUR 267 |
|
Description: Please check the datasheet of Ag Rapid AIV Ag Test Kit before using the test. |
|||
Ag Rapid H5AIV Ag test kit |
|||
| RG15-05 | Bionote | 1 box | EUR 463 |
|
Description: Please check the datasheet of Ag Rapid H5AIV Ag test kit before using the test. |
|||
Rapid PED Ag Test Kit |
|||
| RG14-01 | Bionote | 1 box | EUR 159.9 |
|
Description: Please check the datasheet of Rapid PED Ag Test Kit before using the test. |
|||
Ag Rapid CIRD-3 Ag Test Kit |
|||
| RG11-09 | Bionote | 1 box | EUR 123.64 |
|
Description: Please check the datasheet of Ag Rapid CIRD-3 Ag Test Kit before using the test. |
|||
Rapid TGE/PED Ag Test Kit |
|||
| RG14-03 | Bionote | 1 box | EUR 240.85 |
|
Description: Please check the datasheet of Rapid TGE/PED Ag Test Kit before using the test. |
|||
Dynamiker Monkeypox Virus Ag Rapid Test |
|||
| DNK-2114-1 | Dynamiker Biotechnology | 20 tests | EUR 585 |
|
Description: The product is a lateral flow chromatographic immunoassay for the qualitative detection of monkeypox virus antigen in human whole blood, serum, plasma or rash exuudate. The kit is intended for professional use only. |
|||
Ag Rapid Bov. TB Ab Test Kit |
|||
| RB23-02 | Bionote | 1 box | EUR 145 |
|
Description: Please check the datasheet of Ag Rapid Bov. TB Ab Test Kit before using the test. |
|||
Ag Rapid FMD NSP Ab Test Kit |
|||
| RB28-02 | Bionote | 1 box | EUR 108.52 |
|
Description: Please check the datasheet of Ag Rapid FMD NSP Ab Test Kit before using the test. |
|||
Bionote Rapid AIV Ag_NDV Ag Test Kit |
|||
| RG15-09 | Bionote | 1 box | EUR 164.52 |
|
Description: Please check the datasheet of Bionote Rapid AIV Ag_NDV Ag Test Kit before using the test. |
|||
Anigen Rapid FIV Ab/FeLV Ag Test Kit |
|||
| RC12-04-DD | Bionote | 10 tests/Kit | EUR 152.2 |
|
Description: Please check the datasheet of Anigen Rapid FIV Ab/FeLV Ag Test Kit before using the test. |
|||
Panbio™ COVID-19 Ag Rapid Test Device |
|||
| 41FK10 | Abbott | 25 Tests/Kit | EUR 96 |
Panbio™ COVID-19 Ag Rapid Test Device (Nasal) |
|||
| 41FK11 | Abbott | 25 Tests/Kit | EUR 95 |
|
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
|||
Anti-SARS-CoV-2 Neutralization Antibody Test Kit (Colloidal gold immunoassay) |
|||
| CP04010 | UnScience | 25T/kit | Ask for price |
|
Description: The Anti-SARS-CoV-2 Neutralization Antibody Test Kit (Serum/Plasma/Whole blood) is a qualitative membrane-based immunoassay for the detection of SARS-CoV-2 neutralizing antibodies in serum, plasma and whole blood. The sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 neutralizing antibodies in the sample combined with the colloidal gold-labeled SARS-CoV-2 spike protein(SP), then spread to the test area. It is captured by coated SP subunit RBDNTD-CTD, to form a complex and gather in the test area (T line). The quality control area is coated with mouse anti-chicken IgY, and the colloidal goldlabeled chicken IgY is captureed to form a complex and aggregate in hte quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample need to be tested again. |
|||
SARS CoV-2 PCR kit |
|||
| PCR-H731-48R | Bioingentech | 48T | EUR 823 |
SARS CoV-2 PCR kit |
|||
| PCR-H731-96R | Bioingentech | 96T | EUR 1113 |
Anti-SARS-CoV-2 Antibody |
|||
| A2061-50 | Biovision | 50 µg | EUR 480 |
SARS-CoV-2 Spike Peptide |
|||
| 9083P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (NT) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
| 9087P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (CT) SARS-CoV-2 Spike RBD peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
| 9091P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
| 9095P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Nucleocapsid Peptide |
|||
| 9099P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (IN) SARS-CoV-2 Nucleocapsid peptide |
|||
SARS-CoV-2 Nucleocapsid Peptide |
|||
| 9103P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (CT) SARS-CoV-2 Nucleocapsid peptide |
|||